Physicians’ attitudes and the management of low-risk prostate cancer in older American men

According to newly published data in JAMA Internal Medicine and discussed on the Reuters web site today, “physician characteristics may play a larger role than disease characteristics when it comes to how patients with low-risk prostate cancer are initially treated.” This won’t come as a big surprise to most experienced prostate cancer advocates. … READ MORE …

The choice of active surveillance: patient and partner perceptions

Two recent papers in the journal Psycho-oncology offer us interesting insights into patients’ (and their partners’) current perceptions about the role of active surveillance in the management of low-risk, localized prostate cancer. … READ MORE …

More data (sorta) from the Phase III trial of NX-1207 in early stage, low-risk prostate cancer

The Nymox Pharmaceutical Corp. seems to have decided to issue data from the Phase III clinical trial of NX-1207 in a series of media releases over time (which is a more than slightly odd way of going about such things). … READ MORE …

New Phase I/II trial of InSightec’s MRI-guided focal ultrasound therapy

According to a media release issued yesterday by the City of Hope medical center in Los Angeles, they have become the first center in the USA to treat a patient with focused, MRI-guided, ultrasound technology using the InSightec system. … READ MORE …

Eligibility criteria for active surveillance among men with low-risk prostate cancer

As regular readers of this blog will be aware, the urology group at Johns Hopkins in Baltimore has, for the past several years, had one of the most restrictive sets of criteria for eligibility for active surveillance as an appropriate method for the management of men initially diagnosed with low- and very low-risk prostate cancer. … READ MORE …

One man’s route to active surveillance as a first-line management strategy

When CT learned that he had low-grade, organ-confined prostate cancer, he did not decide to get surgical or other therapeutic interventions immediately, based on the guidance of the first doctors he saw. Instead, he decided to actively monitor his disease and adjust his lifestyle habits with guidance from a team of specialists. … READ MORE …

Use of imaging tests in low-risk prostate cancer — striking the right balance

An article published a couple of weeks ago in the Journal of the National Cancer Institute looks at the effects of a physician education campaign in Sweden to reduce the inappropriate use of bone scans and other imaging tests among men with an initial diagnosis of low-risk prostate cancer. … READ MORE …

The over-treatment of low-risk disease in the Medicare community

So there’s a lot of media coverage this morning about an article in the Journal of the American Medical Association suggesting that, here in the USA, more men with low-risk forms of localized prostate cancer are getting more expensive types of treatment for their cancer (and that much of this treatment may be of dubious value). … READ MORE …

Of cost, quality, and care for low-risk prostate cancer

A newly published study in the Annals of Internal Medicine has offered an analysis of the cost-effectiveness of “observation” as compared to immediate initial treatment for men diagnosed with low-risk, localized prostate cancer. … READ MORE …

Ablatherm HIFU data on low-risk patients from the @-Registry

A new study to be presented at the upcoming annual meeting of the American Urological Association in San Diego will provide data on the first-line treatment of some 358 men with low-risk prostate cancer collected in the @-Registry, all of whom received treatment with high-intensity focused ultrasound (HIFU) using the Ablatherm® form of this technology. … READ MORE …

When will what they say correspond to what they do?

In reading through the abstracts of the presentations to be given at the upcoming annual meeting of the American Urological Association (AUA), the results of a national survey of radiation oncologists and urologists on active surveillance (AS) for low-risk prostate cancer is the most striking item that we have seen to date. … READ MORE …

Data from a formal Phase I trial of MR-guided, focal laser surgery

A paper on line in the journal Radiology offers some of the earliest, formally published data from a major academic medical center on the clinical use of focal laser ablation in the treatment of low-risk prostate cancer. … READ MORE …

MRI-guided focused ultrasound in focal treatment of low-risk, localized prostate cancer

In October last year, the US Food and Drug Administration approved the ExAblate MRI-guided focused ultrasound technology for the treatment of pain associated with cancer metastasis to bones, which is obviously a potential benefit for men with late stage, metastatic prostate cancer. … READ MORE …

Relative cost-effectiveness of SBRT and IMRT in treatment of localized prostate cancer

A new paper in the Journal of Oncology Practice has attempted to compare the cost-effectiveness of stereotactic body radiation therapy (SBRT) to that of intensity-modulated radiation therapy (IMRT) in the treatment of men with low- to intermediate-risk prostate cancer. … READ MORE …

NX-1207: an investigational treatment for men with low-risk, localized prostate cancer

Nymox Pharmaceutical Corp. has announced the initiation of patient enrollment for a Phase II trial of NX-1207 for the treatment of men with low-risk, localized prostate cancer. This product is already in Phase III clinical trials in Europe and the USA for the treatment of men with benign prostatic hyperplasia (BPH). … READ MORE …